Abstract
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as correlates of risk and as correlates of protection against COVID-19. Analyses are conducted in the U.S. cohort of baseline SARS-CoV-2 negative per-protocol participants using a case-cohort design that measures the markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7 days post antibody measurement and from 639 vaccine recipient non-cases. All markers are inversely associated with COVID-19 risk and directly associated with vaccine efficacy. In vaccine recipients with nAb ID50 titers of 50, 100, and 7230 international units (IU50)/ml, vaccine efficacy estimates are 75.7% (49.8%, 93.2%), 81.7% (66.3%, 93.2%), and 96.8% (88.3%, 99.3%). The results support potential cross-vaccine platform applications of these markers for guiding decisions about vaccine approval and use.
Introduction
Identifying "correlates of protection" (CoPs)—measurable biomarkers that statistically relate to the level of protection a vaccine provides—is a critical goal in vaccine development. For COVID-19, establishing these correlates is vital for immuno-bridging, which allows regulators to approve vaccines for new populations or variant-specific boosters based on immunogenicity data rather than large-scale clinical trials. Furthermore, CoPs enable cross-platform comparisons, determining if standardized units of protection are consistent across different vaccine technologies, such as mRNA, viral vector, and protein-subunit platforms like Novavax (NVX-CoV2373).
Methods
This study utilized a case-cohort design within the PREVENT-19 Phase 3 trial (NCT04611802). The analysis focused on the U.S. cohort of participants who were SARS-CoV-2 negative at baseline. Immune markers were measured two weeks post-dose two (Day 35) from 12 breakthrough COVID-19 cases and 639 non-cases.
Key assays included the Meso Scale Discovery (MSD) platform for binding antibodies (anti-spike and anti-RBD IgG) and the Monogram PhenoSense assay for pseudovirus neutralizing antibodies (nAb ID50). To facilitate cross-trial comparisons, all results were converted to WHO International Units (BAU/ml for binding antibodies and IU50/ml for neutralization). Statistical modeling employed marginalized Cox proportional hazards models and a machine-learning-based "SuperLearner" to adjust for baseline risk factors such as age, BMI, and geographic location.
Results
Antibody Levels as Correlates of Risk
All three primary immune markers—Spike IgG, RBD IgG, and nAb ID50—showed a significant inverse association with the risk of symptomatic COVID-19. Participants who did not contract the virus (non-cases) exhibited antibody levels approximately three times higher than those who experienced breakthrough infections. For every 10-fold increase in antibody levels, the hazard ratio for symptomatic COVID-19 was estimated between 0.35 and 0.39, representing a 60-65% reduction in risk.
Vaccine Efficacy Thresholds
Vaccine efficacy (VE) was directly associated with antibody concentrations. At a neutralizing antibody level of 50 IU50/ml, the estimated VE was 75.7%. This rose to 81.7% at 100 IU50/ml and reached 96.8% at the highest evaluated level of 7230 IU50/ml. Notably, even participants with the lowest detectable antibody levels maintained a baseline VE of approximately 70-75%, suggesting that other immune components, such as memory B-cells or T-cells, contribute to the "floor" of protection.
Discussion
A major finding of this study is the consistency of the relationship between antibody levels and protection across different vaccine platforms. The correlation observed for the protein-subunit NVX-CoV2373 vaccine aligns closely with data from mRNA (COVE trial) and viral vector (ENSEMBLE and COV002 trials) platforms. This harmony supports the use of standardized antibody thresholds to guide future vaccine approvals and booster strategies.
Limitations of the study include the small number of breakthrough cases (n=12) due to high vaccine efficacy, which resulted in wide confidence intervals. Additionally, the study was conducted during the prevalence of Alpha and Delta variants; further research is required to determine how these correlates shift against more immune-evasive variants like Omicron and to assess the durability of protection following booster doses.
Summary updated